- Conditions
- Discoid Lupus Erythematosus
- Interventions
- Delgocitinib cream, Delgocitinib cream vehicle
- Drug
- Lead sponsor
- LEO Pharma
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 5
- States / cities
- San Diego, California • Skokie, Illinois • Boston, Massachusetts + 2 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1081–1104
of 10,564
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors
- Interventions
- Sunitinib (CLOSED TO ENROLLMENT), Trastuzumab and Pertuzumab (CLOSED TO ENROLLMENT), Vemurafenib and Cobimetinib (CLOSED TO ENROLLMENT), Olaparib (CLOSED TO ENROLLMENT), Nivolumab and Ipilimumab (CLOSED TO ENROLLMENT), Abemaciclib (CLOSED TO ENROLLMENT), Talazoparib (CLOSED TO ENROLLMENT), Atezolizumab and Talazoparib (CLOSED TO ENROLLMENT), Tucatinib plus Trastuzumab Subcutaneous (SC) (CLOSED TO ENROLLMENT), Futibatinib, Dabrafenib plus Trametinib, Fam-Trastuzumab Deruxtecan-Nxki (TDxD)
- Drug
- Lead sponsor
- American Society of Clinical Oncology
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 4,200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2028
- U.S. locations
- 174
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Auburn, California + 137 more
- Conditions
- Post Operative Pain
- Interventions
- AtriCure Cryo Nerve Block (cryoNB) Device Family
- Device
- Lead sponsor
- AtriCure, Inc.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 5,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2040
- U.S. locations
- 7
- States / cities
- Jacksonville, Florida • Orlando, Florida • Annapolis, Maryland + 4 more
- Conditions
- Cervical Carcinoma, Human Papillomavirus Infection
- Interventions
- Biospecimen Collection, Cervical Biopsy, Colposcopy, Electronic Health Record Review, Endocervical Curettage, Excision, HPV Self-Collection, Human Papillomavirus Test, Questionnaire Administration
- Procedure · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 25 Years and older · Female only
- Enrollment
- 500 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2027
- U.S. locations
- 11
- States / cities
- Atlanta, Georgia • Louisville, Kentucky • Ann Arbor, Michigan + 8 more
- Conditions
- Age-related Macular Degeneration
- Interventions
- Fovista® (anti-PDGF BB) plus anti-VEGF
- Drug
- Lead sponsor
- Ophthotech Corporation
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 101 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 13
- States / cities
- Phoenix, Arizona • Beverly Hills, California • Sacramento, California + 9 more
- Conditions
- HIV-1 Infection
- Interventions
- ABC/DTG/3TC, B/F/TAF, ABC/DTG/3TC Placebo, B/F/TAF Placebo
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 631 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 78
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 57 more
- Conditions
- Heart Failure
- Interventions
- Sentus QP left ventricular lead
- Device
- Lead sponsor
- Biotronik SE & Co. KG
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,226 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 75
- States / cities
- Fairhope, Alabama • Anchorage, Alaska • Chula Vista, California + 64 more
- Conditions
- COPD
- Interventions
- AQX-1125, Placebo
- Drug
- Lead sponsor
- Aquinox Pharmaceuticals (Canada) Inc.
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Idiopathic Hypersomnia, Excessive Daytime Sleepiness
- Interventions
- Pitolisant
- Drug
- Lead sponsor
- Harmony Biosciences Management, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 119 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 32
- States / cities
- Los Angeles, California • San Ramon, California • Brandon, Florida + 29 more
- Conditions
- Primary Amenorrhea With Hypogonadotropic Hypogonadism
- Interventions
- Gonadorelin acetate subcutaneous (SC) 10 μg/pulse as a fixed dose, administered via. OmniPod pump, Gonadorelin acetate SC 15 μg/pulse as a fixed dose, administered via. OmniPod pump, Gonadorelin acetate SC 20 μg/pulse as a fixed dose, administered via. OmniPod pump, Placebo (SC 10, 15, or 20 μg/pulse as a fixed dose, administered via. OmniPod pump)
- Drug
- Lead sponsor
- Ferring Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 40 Years · Female only
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 33
- States / cities
- Tempe, Arizona • San Francisco, California • Aurora, Colorado + 28 more
- Conditions
- Candidiasis, Oral, HIV Infections
- Interventions
- Amphotericin B
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 13 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 1998
- U.S. locations
- 30
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Jose, California + 18 more
- Conditions
- Type 2 Diabetes
- Interventions
- Dapagliflozin, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 833 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 45
- States / cities
- Huntsville, Alabama • Ozark, Alabama • Anaheim, California + 42 more
- Conditions
- Lymphoma
- Interventions
- rituximab, fludarabine phosphate
- Biological · Drug
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2001
- U.S. locations
- 14
- States / cities
- Tucson, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 8 more
- Conditions
- Alagille Syndrome
- Interventions
- LUM001, Placebo
- Drug
- Lead sponsor
- Mirum Pharmaceuticals, Inc.
- Industry
- Eligibility
- 12 Months to 18 Years
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 12
- States / cities
- Los Angeles, California • San Francisco, California • Aurora, Colorado + 9 more
- Conditions
- Growth and Development
- Interventions
- Everolimus
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 0 Years to 17 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2023
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Saint Paul, Minnesota • Cincinnati, Ohio + 1 more
- Conditions
- Eosinophilic Gastritis, Eosinophilic Duodenitis
- Interventions
- lirentelimab (AK002), Placebo
- Drug · Other
- Lead sponsor
- Allakos Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 181 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 60
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Gilbert, Arizona + 54 more
- Conditions
- Lymphoma
- Interventions
- CHOP regimen, cyclophosphamide, doxorubicin hydrochloride, prednisone, vincristine sulfate, tositumomab and iodine I 131 tositumomab
- Drug · Radiation
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1999
- U.S. locations
- 87
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 56 more
- Conditions
- Blepharoptosis
- Interventions
- RVL-1201, Vehicle ophthalmic solution
- Drug · Other
- Lead sponsor
- RVL Pharmaceuticals, Inc.
- Industry
- Eligibility
- 9 Years and older
- Enrollment
- 234 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 35
- States / cities
- Phoenix, Arizona • Garden Grove, California • Mission Hills, California + 30 more
- Conditions
- Hypercholesterolemia
- Interventions
- LIB003
- Biological
- Lead sponsor
- LIB Therapeutics LLC
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 63 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Breast Cancer
- Interventions
- Bevacizumab, Standard adjuvant chemotherapy
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,591 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2014
- U.S. locations
- 44
- States / cities
- Huntsville, Alabama • Mobile, Alabama • Fayetteville, Arkansas + 40 more
- Conditions
- Seizures, Epilepsy
- Interventions
- levetiracetam
- Drug
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- 1 Day to 30 Days
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Type 2 Diabetes, Cortisol Excess
- Interventions
- clofutriben, Placebo
- Drug
- Lead sponsor
- Sparrow Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 61
- States / cities
- Chandler, Arizona • Tucson, Arizona • Fountain Valley, California + 53 more
- Conditions
- Acute Kidney Injury, Adverse Drug Reaction, Acute Kidney Failure, Kidney Failure, Kidney Disease
- Interventions
- Not listed
- Lead sponsor
- Ravindra Mehta
- Other
- Eligibility
- 2 Years and older
- Enrollment
- 634 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 8
- States / cities
- Birmingham, Alabama • San Diego, California • Aurora, Colorado + 4 more
- Conditions
- Gout
- Interventions
- Placebo, RDEA3170 5 mg, RDEA3170 10 mg, RDEA3170 12.5 mg
- Drug
- Lead sponsor
- Ardea Biosciences, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 172 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 49
- States / cities
- Birmingham, Alabama • Gulf Shores, Alabama • Mobile, Alabama + 45 more